[A24-37 ] Gadopiclenol (contrast-enhanced magnetic resonance imaging) – Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2024
Project no.:
A24-37
Commission:
Commission awarded on 02.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Diagnostics
Adults and children aged 2 years and older for contrast-enhanced MRI to improve detection and visualization of pathologies with disruption of the blood-brain-barrier and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the CNS
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A24-37